Novartis   link
Location: Basel
Hauptporte - MainGate, Fabrikstrasse 2, 4056 Basel

Discipline: Pharmacology

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.


Pharmacology - Health - Feb 26
Adds tislelizumab, a uniquely designed anti-PD-1 monoclonal antibody for monotherapy and proprietary combination cancer therapies with Novartis portfolio and pipeline therapies Novartis will co-develop tislelizumab with BeiGene and expand access to patients in North America, Europe and Japan Specifically designed to minimize binding to Fc'R on m
Pharmacology - Health - Feb 26

Cosentyx (secukinumab) is the first biologic with proven efficacy in all 6 key manifestations of psoriatic arthritis (PsA), and the only biologic with fast and lasting relief of axial manifestations of PsA in a dedicated trial 1,2 ,3 .

Health - Pharmacology - Feb 16

Multicenter survey results show MS patients and nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta over other autoinjectors for their current treatment (84% vs 16%) 1   Sensoready autoinjector pen ranked highest for "easy to perform self-injection with the pen," "patient able to use independently" and

Pharmacology - Economics - Feb 11

Sandoz to acquire three established brands sold in more than 100 markets - Acquisition, including leading global brand Zinnat , confirms Sandoz commitment to antibiotics, following plans to expand its integrated manufacturing site in Kundl Transaction complements Sandoz leadership in generic penicillins with a leading position in cephalosporins

Pharmacology - Health - Jan 29

First of multiple agreements being explored by Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine Initial agreement signed with BioNTech to use Novartis manufacturing plant in Stein, Switzerland, to support production of mRNA COVID-19 vaccine Production to commence in th

Pharmacology - Health - Jan 29

  Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS 1 CHMP opinion is based on two Phase III ASCLEPIOS studies that met the primary endpoints where Kesimpta showed a reduction of the annual relapses by over 50% versus teri

Health - Pharmacology - Feb 17

Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation  Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies Effort expands on Novartis commit

Pharmacology - Health - Feb 16

Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF) 1-3   Expanded indication enables potential treatment of more adults with l

Pharmacology - Health - Feb 8

Designation in patients with chronic myeloid leukemia (CML) resistant or intolerant to prior treatments based on positive data from pivotal Phase III ASCEMBL trial evaluating asciminib, an investigational treatment specifically targeting the ABL myristoyl pocket (STAMP) 1 ,2   Despite advances in CML care, many patients are at risk of disease pr

Health - Pharmacology - Jan 29

  Novartis leprosy medicine donation program with WHO extended to 2025 Program has already treated over 7 million patients since 2000 New evidence from contact tracing and preventive treatment program shows route to accelerate elimination Basel, January 29, 2021 - A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive the global push towards making leprosy history.

Pharmacology - Health - Jan 26

Full year net sales from continuing operations¹ up 3% (cc², +3% USD): - Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc), Ilaris (+31% cc) and the Xiidra acquisition (+95% cc) Oncology BU grew 3% (cc) driven by Promacta/Revolade (+23% cc), Jakavi (+20% cc), Kisqali (+45

Website Preview